Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B S Coller

Showing results (151-160 of 163) with videos related to

Pageof 17
Sort By:
The Journal of Clinical Investigation|August 1, 1990
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectorisH K Gold, L W Gimple, T Yasuda, et al.
Annals of the New York Academy of Sciences|January 1, 1991
Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agentsB S Coller, L E Scudder, J Beer, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 26, 1998
Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximabG Dangas, J J Badimon, B S Coller, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1985
Thrombus radioimmunoscintigraphy: an approach using monoclonal antiplatelet antibodyZ H Oster, S C Srivastava, P Som, et al.
The American Journal of Cardiology|May 10, 2000
Antithrombotic effects of abciximabR Hayes, J H Chesebro, V Fuster, et al.
Circulation|September 1, 1989
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activatorL W Gimple, H K Gold, R C Leinbach, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|February 29, 2000
Measuring faculty effort and contributions in medical educationD O Nutter, J S Bond, B S Coller, et al.
Blood|December 23, 1999
A naturally occurring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIbbeta3R B Basani, D L French, G Vilaire, et al.
The Journal of Clinical Investigation|January 23, 1999
Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survivalK M Hodivala-Dilke, K P McHugh, D A Tsakiris, et al.
The Journal of Clinical Investigation|April 1, 1988
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogsT Yasuda, H K Gold, J T Fallon, et al.
Pageof 17

Showing results (151-160 of 163) with videos related to

Sort By:
Pageof 17
The Journal of Clinical Investigation|August 1, 1990
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectorisH K Gold, L W Gimple, T Yasuda, et al.
Annals of the New York Academy of Sciences|January 1, 1991
Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agentsB S Coller, L E Scudder, J Beer, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|August 26, 1998
Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximabG Dangas, J J Badimon, B S Coller, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1985
Thrombus radioimmunoscintigraphy: an approach using monoclonal antiplatelet antibodyZ H Oster, S C Srivastava, P Som, et al.
The American Journal of Cardiology|May 10, 2000
Antithrombotic effects of abciximabR Hayes, J H Chesebro, V Fuster, et al.
Circulation|September 1, 1989
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activatorL W Gimple, H K Gold, R C Leinbach, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|February 29, 2000
Measuring faculty effort and contributions in medical educationD O Nutter, J S Bond, B S Coller, et al.
Blood|December 23, 1999
A naturally occurring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIbbeta3R B Basani, D L French, G Vilaire, et al.
The Journal of Clinical Investigation|January 23, 1999
Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survivalK M Hodivala-Dilke, K P McHugh, D A Tsakiris, et al.
The Journal of Clinical Investigation|April 1, 1988
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogsT Yasuda, H K Gold, J T Fallon, et al.
Pageof 17